For instance, in the phase I dose-escalation and dose-expansion study of trastuzumab duocarmazine, 9/32 (28%) patients with HER2-low/HR+ breast cancer and 6/15 (40%) patients with HER2-low/HR− breast cancer exhibited an objective response. The gene discussed is ERBB2; the disease is breast cancer.